As previously introduced, we all have known that RRx-001, a hypoxia-selective epigenetic agent and a radio- and chem-sensitizer. Additionally, it triggers apoptosis and overcomes drug resistance in myeloma. RRx-001 exhibits…
The blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer therapy. However, the antibody-based immunotherapies carry a number of disadvantages, including the high…
Programmed death protein 1 (PD-1) is a major immunological checkpoint that belongs to the CD28 family. Importantly, it has an essential role in balancing protective immunity and immunopathology, homeostasis and…
In cancer treatment, checkpoint inhibition of adaptive immunity is an important breakthrough of epoch-making significance. However, this therapy doesn’t work to many patients. Interestingly, researchers found that these non-responders usually…